Compare CTKB & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | DNA |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.1M | 562.3M |
| IPO Year | 2021 | N/A |
| Metric | CTKB | DNA |
|---|---|---|
| Price | $5.37 | $10.24 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $5.70 | ★ $10.50 |
| AVG Volume (30 Days) | 785.4K | ★ 886.1K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,828,000.00 | $180,606,000.00 |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $5.45 | $3.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.37 | $5.00 |
| 52 Week High | $6.18 | $17.58 |
| Indicator | CTKB | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 59.42 |
| Support Level | $5.21 | $8.82 |
| Resistance Level | $5.70 | $11.10 |
| Average True Range (ATR) | 0.26 | 0.62 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 38.64 | 70.44 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.